BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for life-threatening severe medical conditions, mainly for children.

Shares have been under pressure over the past year, dropping -22% over the past 52 weeks as rising interest rates and general pessimism within the biotechnology sector has tamped down investor interest, but have been on the rebound in more recent 4 weeks at +8%.

The recent positive momentum came from a strong beat on the top and bottom line (+4 and +30%, respectively) as the company reported strong demand for its top two products Voxzogo for achondroplasia and Palynziq for PKU. This delivered revenue of $2.85 billion for the full year, surpassing the company’s own high-end guidance. Investors also cheered cost synergies, with the company’s $500 million cost optimization program implemented in 2024 drove operating margins 900 basis points higher.

At just 16x 2025 EPS estimates, with building earnings momentum as analysts revise estimates upward, we believe the stock is ready for a move higher in the coming weeks and months.